FDA Greenlights Osteoporosis Drug for Postmenopausal Women
FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
Safety Risk with Higher Dose Tofacitnib
Tainted Research Repeatedly Re-Used to Assess Drug Effectiveness
U.S. FDA Chief Gottlieb Resigns
Upadacitinib at the FDA
Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone
FDA Advisory Committee Votes in Favor of Romosozumab Approval
FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
- 1
- 2
- 3
- …
- 5
- Next Page »